U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Epithelioid Mesothelioma

MedGen UID:
1782245
•Concept ID:
C5446866
•
Neoplastic Process

Definition

The reemergence of epithelioid mesothelioma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Epithelioid Mesothelioma

Professional guidelines

PubMed

Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
Hjerpe A, Abd-Own S, Dobra K
Arch Pathol Lab Med 2018 Aug;142(8):893-901. doi: 10.5858/arpa.2018-0020-RA. PMID: 30040460
Vulvar sarcomas: Short guideline for histopathological recognition and clinical management. Part 2.
Chokoeva AA, Tchernev G, Cardoso JC, Patterson JW, Dechev I, Valkanov S, Zanardelli M, Lotti T, Wollina U
Int J Immunopathol Pharmacol 2015 Jun;28(2):178-86. Epub 2015 Mar 26 doi: 10.1177/0394632015575977. PMID: 25816393
Pathohistological diagnosis and differential diagnosis.
Tischoff I, Neid M, Neumann V, Tannapfel A
Recent Results Cancer Res 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. PMID: 21479896

Recent clinical studies

Etiology

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S, Arnaud A, Orbach D, Andre N, Berger C, Kepenekian V, Brigand C, Fresneau B, Poli-Merol ML, Habougit C, Varlet F, Scalabre A
Pediatr Blood Cancer 2020 Jun;67(6):e28286. Epub 2020 Apr 11 doi: 10.1002/pbc.28286. PMID: 32277799
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup
Lancet Oncol 2019 Feb;20(2):239-253. Epub 2019 Jan 16 doi: 10.1016/S1470-2045(18)30765-4. PMID: 30660609
Pathohistological diagnosis and differential diagnosis.
Tischoff I, Neid M, Neumann V, Tannapfel A
Recent Results Cancer Res 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. PMID: 21479896

Diagnosis

New developments in mesothelial pathology.
Churg A
Histopathology 2024 Jan;84(1):136-152. Epub 2023 Sep 11 doi: 10.1111/his.15007. PMID: 37694811
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI, Tjota MY, Gao G, Mitchell O, Kindler H, Segal J, Husain AN, Mueller J, Schulte JJ
Am J Clin Pathol 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041. PMID: 37141416
Molecular characterization of localized pleural mesothelioma.
Hung YP, Dong F, Dubuc AM, Dal Cin P, Bueno R, Chirieac LR
Mod Pathol 2020 Feb;33(2):271-280. Epub 2019 Aug 1 doi: 10.1038/s41379-019-0330-9. PMID: 31371807Free PMC Article
Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
Hjerpe A, Abd-Own S, Dobra K
Arch Pathol Lab Med 2018 Aug;142(8):893-901. doi: 10.5858/arpa.2018-0020-RA. PMID: 30040460
Pathohistological diagnosis and differential diagnosis.
Tischoff I, Neid M, Neumann V, Tannapfel A
Recent Results Cancer Res 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. PMID: 21479896

Therapy

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S, Arnaud A, Orbach D, Andre N, Berger C, Kepenekian V, Brigand C, Fresneau B, Poli-Merol ML, Habougit C, Varlet F, Scalabre A
Pediatr Blood Cancer 2020 Jun;67(6):e28286. Epub 2020 Apr 11 doi: 10.1002/pbc.28286. PMID: 32277799
Diffuse epithelioid malignant mesothelioma of the pleura presenting as a hydropneumothorax and vertebral body invasion.
Hinkamp CA, Dalal SN, Butt Y, Cabo Chan AV
BMJ Case Rep 2020 Jan 2;13(1) doi: 10.1136/bcr-2019-231987. PMID: 31900296Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup
Lancet Oncol 2019 Feb;20(2):239-253. Epub 2019 Jan 16 doi: 10.1016/S1470-2045(18)30765-4. PMID: 30660609

Prognosis

Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI, Tjota MY, Gao G, Mitchell O, Kindler H, Segal J, Husain AN, Mueller J, Schulte JJ
Am J Clin Pathol 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041. PMID: 37141416
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S, Arnaud A, Orbach D, Andre N, Berger C, Kepenekian V, Brigand C, Fresneau B, Poli-Merol ML, Habougit C, Varlet F, Scalabre A
Pediatr Blood Cancer 2020 Jun;67(6):e28286. Epub 2020 Apr 11 doi: 10.1002/pbc.28286. PMID: 32277799
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Pathohistological diagnosis and differential diagnosis.
Tischoff I, Neid M, Neumann V, Tannapfel A
Recent Results Cancer Res 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. PMID: 21479896

Clinical prediction guides

New developments in mesothelial pathology.
Churg A
Histopathology 2024 Jan;84(1):136-152. Epub 2023 Sep 11 doi: 10.1111/his.15007. PMID: 37694811
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI, Tjota MY, Gao G, Mitchell O, Kindler H, Segal J, Husain AN, Mueller J, Schulte JJ
Am J Clin Pathol 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041. PMID: 37141416
Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
Dagogo-Jack I, Madison RW, Lennerz JK, Chen KT, Hopkins JF, Schrock AB, Ritterhouse LL, Lester A, Wharton KA Jr, Mino-Kenudson M, Danziger N, Hung YP, Mata DA, Ross JS
JCO Precis Oncol 2022 Jun;6:e2100422. doi: 10.1200/PO.21.00422. PMID: 35704798
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA, Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S
Nat Genet 2016 Apr;48(4):407-16. Epub 2016 Feb 29 doi: 10.1038/ng.3520. PMID: 26928227

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...